PCSA · Processa Pharmaceuticals, Inc.
$1.81
-0.05 (-2.69%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 14, 2026
The latest filing states the doubt was alleviated.
“Following our acquisition of Vidya and closing of the related $200 million gross private placement (from which we received net proceeds of $183.3 million) on July 30, 2026, we believe our cash and cash equivalents will be sufficient to satisfy our cash requirements over the next 12 months and beyond. This represents a material change from what we reported in our 2025 Form 10-K that disclosed substantial doubt of our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$5.06M
Shares
2.79M
Volume · Oct 23
35.05K
Avg daily vol (3M)
266.29K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.81
Open$1.76
Day$1.75–1.90
52W close$1.35–9.73
Avg vol 30d136K
Short int4K · 0.1% float · 1.0d
Short vol38%
Last earningsMar 31, 2023
DataJan 2020–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
call held Mar 31, 2023
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$13.44M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
1.8
Trailing earnings · reciprocal yield 55.2%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$196,325
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+337.5%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.1%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 19.5 · elevated
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−25%
below
Price vs 50-day avg
−4%
below
RSI (14)
52
neutral
MACD trend
Positive
52-week position
5%
near low
Momentum
relative strength
1-month return
−2%
trailing
6-month return
−32%
trailing
YTD return
−37%
this year
Relative strength
−38%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+20% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.15% of float · ▼ -72.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
12 holders — mid 3-yr range
Squeeze score
39
low risk · 0–100
Fundamentals
Revenue growth
−96%
Y/Y
Gross margin
100%
expanding
EPS growth
+89%
Y/Y
Free cash flow
$-11.4M
Balance sheet
$5.5M
net cash
Quant / Vol
risk profile
Volatility
178%
annualized · 1-yr
Max drawdown
−86%
past year
ATR
10.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 13, 2021
Clinical trial costs
· current
$3M – $5M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−25%
Bearish
Price vs 50-day avg
−4%
Neutral
RSI (14)
52
Neutral
MACD trend
Positive
Bullish
52-week position
5%
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+20% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.15% of float · ▼ -72.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
12 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $2 · 5%
Range high $10
vs 200-day avg -25%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PCSA
this stock
Processa Pharmaceuticals, Inc.
|
$5.06M | -37.2% | -95.6% | — | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.80B | +15.6% | +46.2% | 30.5 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.88B | +4.3% | +20.8% | 19.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.89B | +578.5% | +4.3% | — | 7.7% |
|
CSLLY
Csl Ltd
|
$66.42B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
SEC Filings
Latest
DEF 14A
- Filed
- Oct 22, 2026
- This year
- 15
Processa Pharmaceuticals, Inc. completed its merger with Vidya Therapeutics, Inc. on July 28, 2026, and will ask stockholders on November 30, 2026 to approve a reverse stock split at a ratio of not less than 1-for-3 and not more than 1-for-9.
ViewEarnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PCSA | +7.1% | -1.6% | -32.5% | +10.4% | -37.2% |
| SPY | -0.4% | -1.5% | +5.8% | -0.4% | +11.5% |
| vs SPY | +7.5% | -0.2% | -38.3% | +10.7% | -48.6% |